Pricing Log in Create free account

Cabaletta Bio, Inc. (CABA) vs Inhibikase Therapeutics, Inc. (IKT)

Cabaletta Bio, Inc. and Inhibikase Therapeutics, Inc. are both Biotechnology companies. Cabaletta Bio, Inc. and Inhibikase Therapeutics, Inc. are of similar size ($262.8M and $255.4M). Across the 9 metrics below, Inhibikase Therapeutics, Inc. leads on 7 and Cabaletta Bio, Inc. on 2.

Valuation

Metric CABA IKT Biotechnology median
P/E n/m n/m 8.50
P/S n/m 1,105.73 9.71
P/B 1.01 1.88 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.07 n/m 0.64
EV/Sales n/m 495.30 9.21
Earnings yield (111.35%) (26.06%) (33.15%)
Free cash flow yield (72.80%) (14.80%) (25.50%)

Profitability

Metric CABA IKT Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (93.20%) (51.96%) (56.36%)
Return on assets (75.36%) (48.04%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CABA IKT Biotechnology median
Revenue growth (TTM) — 110.93% 6.02%
EPS growth (last fiscal year) 10.26% 57.76% 30.26%
Revenue growth, 5-year CAGR — (42.21%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CABA IKT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.79 15.82 4.72
Net debt to EBITDA 0.84 3.44 0.96

Dividend

Metric CABA IKT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CABA IKT Biotechnology median
Market cap 262.79m 255.35m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack